Trials / Completed
CompletedNCT01493713
Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
Phase 4 Study to Evaluate Correlation of Overall Response According to RECIST-conventional Imaging Techniques, Morphologic Response by CT, & Histopathologic Response in Patients With Hepatic Metastasis Secondary to Colorectal Cancer With Bevacizumab in Combination With XELOX
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to to evaluate the correlation of overall objective response according to RECIST v1.1. criteria evaluated by conventional imaging techniques, morphologic response by CT, and histopathologic response in patients with resectable hepatic metastasis secondary to colorectal cancer treated with bevacizumab in combination with XELOX.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Evaluate the correlation of overall different objective response. | Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography) |
Timeline
- Start date
- 2011-11-16
- Primary completion
- 2014-12-08
- Completion
- 2017-12-18
- First posted
- 2011-12-16
- Last updated
- 2018-02-19
Locations
21 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01493713. Inclusion in this directory is not an endorsement.